HLA Ligand Atlas

HLA Ligand Atlas provides a comprehensive collection of human leukocyte antigen (HLA) ligands identified by mass spectrometry from benign tissues to support analysis of HLA-I and HLA-II peptide presentation across tissues, individuals, alleles, and non-canonical genomic regions.

Key Features:

• Mass spectrometry aggregation: Aggregates data from over 1,000 mass spectrometry experiments.
• Sample composition: Contains data from 225 benign samples derived from 29 tissues and 21 subjects.
• Ligand counts: Includes 89,853 HLA-I ligands and 140,861 HLA-II ligands.
• HLA allele specificity: Covers a wide range of HLA-I and HLA-II allotypes for allele-specific analyses.
• Tissue and individual variability: Captures variability of immunopeptidomes between tissues and individuals at the source protein and HLA-ligand levels.
• Non-canonical genomic regions: Identifies 1,407 HLA-I ligands originating from non-canonical genomic regions.
• Comparative analysis capability: Enables comparative analyses between benign and malignant tissues to identify tumor-associated antigens.

Scientific Applications:

• Cancer Immunotherapy: Supports identification of tumor-associated antigens by comparing benign and malignant tissue ligandomes.
• Infection Studies: Provides peptide-level data to study pathogen–host immune interactions relevant to vaccine development and infectious disease research.
• Transplantation Medicine: Informs strategies to improve graft acceptance and reduce rejection by identifying HLA ligands involved in immune recognition.
• Allergy and Autoimmunity Research: Aids in mapping peptides presented by HLA molecules in tissues to elucidate mechanisms of allergic reactions and autoimmune diseases.

Methodology:

Data originate from mass spectrometry experiments aggregated across samples and were used for comparative analyses between benign and malignant tissues.